Comment on: Evaluation of erythrocyte and reticulocyte parameters as indicative of iron deficiency in patients with anemia of chronic disease

Piva, Elisa

doi:10.1016/j.bjhh.2015.02.005

Cited by 7 publications

(11 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To diagnose ID in HF and other conditions one would have to measure the iron parameters serum iron, serum transferrin, %Transferrin Saturation (%TSat), and serum ferritin [ 114 , 115 , 116 , 117 , 118 ] in any patient suspected of having ID and not just measure them in those with anemia.. The two commonly used tests that are used to detect ID are %TSat and serum ferritin.…”

Section: Diagnosis and Treatment Of Idmentioning

confidence: 99%

“…There is no test that can predict very accurately the degree of response to IV iron in HF or RF or in other inflammatory conditions with great accuracy [ 114 , 115 , 116 , 117 , 118 ]. Some suggest that analysis of the soluble transferrin receptor best reflects unmet cellular iron requirements and is the most accurate measurement for predicting the severity of the ID and the response to IV iron [ 116 ].…”

Section: Diagnosis and Treatment Of Idmentioning

confidence: 99%

“…Some suggest that analysis of the soluble transferrin receptor best reflects unmet cellular iron requirements and is the most accurate measurement for predicting the severity of the ID and the response to IV iron [ 116 ]. Others suggest the use of various red cell parameters such as the percentage of microcytic erythrocytes or hypochromic erythrocytes, or the level of hemoglobin in reticulocytes and mature red blood cells [ 117 , 118 ]. Others suggest that hepcidin best predicts Hb response to oral iron [ 119 ].…”

Section: Diagnosis and Treatment Of Idmentioning

confidence: 99%

See 2 more Smart Citations

Is Correction of Iron Deficiency a New Addition to the Treatment of the Heart Failure?

Silverberg

Wexler²,

Schwartz

2015

IJMS

View full text Add to dashboard Cite

Anemia is present in about 40% of heart failure (HF) patients. Iron deficiency (ID) is present in about 60% of the patients with anemia (about 24% of all HF patients) and in about 40% of patients without anemia (about 24% of all HF patients). Thus ID is present in about half the patients with HF. The ID in HF is associated with reduced iron stores in the bone marrow and the heart. ID is an independent risk factor for severity and worsening of the HF. Correction of ID with intravenous (IV) iron usually corrects both the anemia and the ID. Currently used IV iron preparations are very safe and effective in treating the ID in HF whereas little information is available on the effectiveness of oral iron. In HF IV iron correction of ID is associated with improvement in functional status, exercise capacity, quality of life and, in some studies, improvement in rate of hospitalization for HF, cardiac structure and function, and renal function. Large long-term adequately-controlled intervention studies are needed to clarify the effect of IV iron in HF. Several heart associations suggest that ID should be routinely sought for in all HF patients and corrected if present. In this paper we present our approach to diagnosis and treatment of iron deficiency in heart failure.

show abstract

Section: Diagnosis and Treatment Of Idmentioning

confidence: 99%

Section: Diagnosis and Treatment Of Idmentioning

confidence: 99%

Section: Diagnosis and Treatment Of Idmentioning

confidence: 99%

See 1 more Smart Citation

Is Correction of Iron Deficiency a New Addition to the Treatment of the Heart Failure?

Silverberg

Wexler²,

Schwartz

2015

IJMS

View full text Add to dashboard Cite

show abstract

“…This indicates that a patient with Ret‐He >27.0 pg is unlikely to have IDA, while allowing for iron supplementation to be initiated in patients with Ret‐He ≤27.0 pg. Given that iron is necessary for effective erythropoiesis, timely and accurate testing of iron status is essential, particularly in certain disease populations . Ret‐He is used as a useful parameter for the monitoring of iron treatment .…”

Section: Discussionmentioning

confidence: 99%

“…Given that iron is necessary for effective erythropoiesis, timely and accurate testing of iron status is essential, particularly in certain disease populations. 19,20 Ret-He is used as a useful parameter for the monitoring of iron treatment. 19 In subjects who remain nonresponsive to iron treatment, further specific laboratory testing of iron, or a thalassemia study may be required.…”

Section: Discussionmentioning

confidence: 99%

Reticulocyte hemoglobin equivalent in a thalassemia‐prevalent area

Kadegasem

Songdej

Lertthammakiat

et al. 2019

Pediatrics International

View full text Add to dashboard Cite

Background Reticulocyte hemoglobin equivalent (Ret‐He), a direct measure of the hemoglobin (Hb) in the young red blood cells, has been reported to be useful in the diagnosis of iron deficiency anemia (IDA) but may have some limitations in thalassemia trait. This study evaluated the differences in Ret‐He in school‐aged children, and assessed the diagnostic value of Ret‐He in identifying IDA in a thalassemia‐prevalent area. Methods Blood samples underwent complete blood count analysis, including Ret‐He, ferritin, serum iron and total iron binding capacity. Blood samples also underwent Hb typing and a molecular study for α‐thalassemia. Receiver operating characteristic analysis was performed to determine the predictive capacity of Ret‐He in the diagnosis of IDA. ID was defined as serum ferritin <30 ng/mL and/or transferrin saturation (TSAT) <16%; IDA was defined as serum ferritin <12 ng/mL and/or TSAT <16% with low Hb for age. Normal healthy children (normal controls: NC) had normal iron study, without the thalassemia trait. Results Ninety‐eight children with a mean age of 12.9 ± 0.6 years were included. Ret‐He in the thalassemia trait group (26.7 ± 2.4 pg), ID group (29.0 ± 2.9 pg), IDA group (25.4 ± 2.7 pg), ID + thalassemia trait group (26.6 ± 2.8 pg), and the IDA + thalassemia trait group (24.6 ± 2.3 pg) was significantly lower than in the NC group (30.8 ± 1.7 pg; P < 0.001, 0.01, 0.006, 0.002 and <0.001, respectively). Ret‐He had an area under the curve of 0.904 in diagnostic ability for IDA, while a cut‐off ≤27 pg had a sensitivity of 91.7% and a specificity of 81%. Conclusion Ret‐He was lowest in subjects with IDA + thalassemia trait. A Ret‐He cut‐off ≤27 pg was suggestive of IDA in the present study.

show abstract

Reticulocyte hemoglobin equivalent as a potential marker for diagnosis of iron deficiency

et al. 2017

View full text Add to dashboard Cite

Comment on: Evaluation of erythrocyte and reticulocyte parameters as indicative of iron deficiency in patients with anemia of chronic disease

Cited by 7 publications

References 32 publications

Is Correction of Iron Deficiency a New Addition to the Treatment of the Heart Failure?

Is Correction of Iron Deficiency a New Addition to the Treatment of the Heart Failure?

Reticulocyte hemoglobin equivalent in a thalassemia‐prevalent area

Reticulocyte hemoglobin equivalent as a potential marker for diagnosis of iron deficiency

Contact Info

Product

Resources

About